Background: Connective tissue growth factor (CTGF) and transforming growth factor β1 (TGF-β1) are emerging biomarkers for tissue fibrosis. The aim of this study was to investigate the association between circulating CTGF, TGF-β1 levels and cardiac diastolic dysfunction in patients with diastolic heart failure (DHF). Methods: Admitted subjects were screened for heart failure and those with left ventricular (LV) ejection fraction <45% were excluded. Diastolic dysfunction was defined as functional abnormalities that exist during LV relaxation and filling by echocardiographic criteria. Totally 114 patients with DHF and 72 controls were enrolled. Plasma levels of CTGF, TGF-β1, and B-type natriuretic peptide (BNP) were determined. Results: The plasma CTGF and TGF-β1 levels increased significantly in patients with DHF. Circulating CTGF and TGF-β1 levels were correlated with echocardiographic parameter E/e’ and diastolic dysfunction grading in DHF patients. In multivariate logistic analysis, CTGF was significantly associated with diastolic dysfunction (odds ratio: 1.027, p < 0.001). Plasma CTGF (AUC: 0.770 ± 0.036, p < 0.001) and CTGF/BNP (AUC: 0.839 ± 0.036, p < 0.001) showed good predictive power to the diagnosis of DHF. Conclusions: This finding suggested CTGF could be involved in the pathophysiology of diastolic heart failure and CTGF/BNP might have auxiliary diagnostic value on diastolic heart failure.

1.
Bhatia
RS
,
Tu
JV
,
Lee
DS
,
Austin
PC
,
Fang
J
,
Haouzi
A
, et al
Outcome of heart failure with preserved ejection fraction in a population-based study
.
N Engl J Med
.
2006
Jul
;
355
(
3
):
260
9
.
[PubMed]
0028-4793
2.
Owan
TE
,
Hodge
DO
,
Herges
RM
,
Jacobsen
SJ
,
Roger
VL
,
Redfield
MM
.
Trends in prevalence and outcome of heart failure with preserved ejection fraction
.
N Engl J Med
.
2006
Jul
;
355
(
3
):
251
9
.
[PubMed]
0028-4793
3.
Schelbert
EB
,
Fonarow
GC
,
Bonow
RO
,
Butler
J
,
Gheorghiade
M
.
Therapeutic targets in heart failure: refocusing on the myocardial interstitium
.
J Am Coll Cardiol
.
2014
Jun
;
63
(
21
):
2188
98
.
[PubMed]
0735-1097
4.
Deswal
A
,
Petersen
NJ
,
Feldman
AM
,
Young
JB
,
White
BG
,
Mann
DL
.
Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)
.
Circulation
.
2001
Apr
;
103
(
16
):
2055
9
.
[PubMed]
0009-7322
5.
Sciarretta
S
,
Paneni
F
,
Palano
F
,
Chin
D
,
Tocci
G
,
Rubattu
S
, et al
Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction
.
Clin Sci (Lond)
.
2009
Mar
;
116
(
6
):
467
77
.
[PubMed]
0143-5221
6.
Dai
QM
,
Lu
J
,
Liu
NF
.
Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor
.
Chin Med J (Engl)
.
2011
Jan
;
124
(
1
):
89
94
.
[PubMed]
2542-5641
7.
Tsutsui
H
,
Matsushima
S
,
Kinugawa
S
,
Ide
T
,
Inoue
N
,
Ohta
Y
, et al
Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart
.
Hypertens Res
.
2007
May
;
30
(
5
):
439
49
.
[PubMed]
0916-9636
8.
Blom
IE
,
Goldschmeding
R
,
Leask
A
.
Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?
Matrix Biol
.
2002
Oct
;
21
(
6
):
473
82
.
[PubMed]
0945-053X
9.
Ohnishi
H
,
Oka
T
,
Kusachi
S
,
Nakanishi
T
,
Takeda
K
,
Nakahama
M
, et al
Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats
.
J Mol Cell Cardiol
.
1998
Nov
;
30
(
11
):
2411
22
.
[PubMed]
0022-2828
10.
Matsui
Y
,
Sadoshima
J
.
Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy
.
J Mol Cell Cardiol
.
2004
Aug
;
37
(
2
):
477
81
.
[PubMed]
0022-2828
11.
Abreu
JG
,
Ketpura
NI
,
Reversade
B
,
De Robertis
EM
.
Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta
.
Nat Cell Biol
.
2002
Aug
;
4
(
8
):
599
604
.
[PubMed]
1465-7392
12.
Koitabashi
N
,
Arai
M
,
Niwano
K
,
Watanabe
A
,
Endoh
M
,
Suguta
M
, et al
Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure
.
Eur J Heart Fail
.
2008
Apr
;
10
(
4
):
373
9
.
[PubMed]
1388-9842
13.
Koitabashi
N
,
Arai
M
,
Kogure
S
,
Niwano
K
,
Watanabe
A
,
Aoki
Y
, et al
Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis
.
Hypertension
.
2007
May
;
49
(
5
):
1120
7
.
[PubMed]
0194-911X
14.
Chinese Society of Cardiology of Chinese Medical Association
;
Editorial Board of Chinese Journal of Cardiology
.
[Chinese guidelines for the diagnosis and treatment of heart failure 2014]
.
Zhonghua Xin Xue Guan Bing Za Zhi
.
2014
Feb
;
42
(
2
):
98
122
.
[PubMed]
0253-3758
15.
Wachtell
K
,
Bella
JN
,
Liebson
PR
,
Gerdts
E
,
Dahlöf
B
,
Aalto
T
, et al
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study
.
Hypertension
.
2000
Jan
;
35
(
1 Pt 1
):
6
12
.
[PubMed]
0194-911X
16.
Nagueh
SF
,
Smiseth
OA
,
Appleton
CP
,
Byrd
BF
 3rd
,
Dokainish
H
,
Edvardsen
T
, et al;
Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri
.
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
.
Eur Heart J Cardiovasc Imaging
.
2016
Dec
;
17
(
12
):
1321
60
.
[PubMed]
2047-2404
17.
Sharma
K
,
Kass
DA
.
Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies
.
Circ Res
.
2014
Jun
;
115
(
1
):
79
96
.
[PubMed]
0009-7330
18.
Paulus
WJ
,
Tschöpe
C
,
Sanderson
JE
,
Rusconi
C
,
Flachskampf
FA
,
Rademakers
FE
, et al
How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology
.
Eur Heart J
.
2007
Oct
;
28
(
20
):
2539
50
.
[PubMed]
0195-668X
19.
Miyazaki
Y
,
Ikeda
Y
,
Shiraishi
K
,
Fujimoto
SN
,
Aoyama
H
,
Yoshimura
K
, et al
Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling
.
PLoS One
.
2012
;
7
(
4
):
e35875
.
[PubMed]
1932-6203
20.
Benjamin
IJ
.
Targeting endoglin, an auxiliary transforming growth factor β coreceptor, to prevent fibrosis and heart failure
.
Circulation
.
2012
Jun
;
125
(
22
):
2689
91
.
[PubMed]
0009-7322
21.
Zhang
Y
,
Edgley
AJ
,
Cox
AJ
,
Powell
AK
,
Wang
B
,
Kompa
AR
, et al
FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy
.
Eur J Heart Fail
.
2012
May
;
14
(
5
):
549
62
.
[PubMed]
1388-9842
22.
Shi-Wen
X
,
Leask
A
,
Abraham
D
.
Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis
.
Cytokine Growth Factor Rev
.
2008
Apr
;
19
(
2
):
133
44
.
[PubMed]
1359-6101
23.
Kemp
TJ
,
Aggeli
IK
,
Sugden
PH
,
Clerk
A
.
Phenylephrine and endothelin-1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes
.
J Mol Cell Cardiol
.
2004
Aug
;
37
(
2
):
603
6
.
[PubMed]
0022-2828
24.
Wu
CK
,
Wang
YC
,
Lee
JK
,
Chang
SN
,
Su
MY
,
Yeh
HM
, et al
Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan diastolic heart failure registry and molecular basis by cellular and animal models
.
Eur J Heart Fail
.
2014
Feb
;
16
(
2
):
163
72
.
[PubMed]
1388-9842
25.
Behnes
M
,
Brueckmann
M
,
Lang
S
,
Weiß
C
,
Ahmad-Nejad
P
,
Neumaier
M
, et al
Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure
.
Clin Res Cardiol
.
2014
Feb
;
103
(
2
):
107
16
.
[PubMed]
1861-0684
26.
Lijnen
PJ
,
Petrov
VV
,
Fagard
RH
.
Induction of cardiac fibrosis by transforming growth factor-beta(1)
.
Mol Genet Metab
.
2000
Sep-Oct
;
71
(
1-2
):
418
35
.
[PubMed]
1096-7192
27.
Lim
H
,
Zhu
YZ
.
Role of transforming growth factor-beta in the progression of heart failure
.
Cell Mol Life Sci
.
2006
Nov
;
63
(
22
):
2584
96
.
[PubMed]
1420-682X
28.
Leask
A
.
TGFbeta, cardiac fibroblasts, and the fibrotic response
.
Cardiovasc Res
.
2007
May
;
74
(
2
):
207
12
.
[PubMed]
0008-6363
29.
Rachfal
AW
,
Brigstock
DR
.
Structural and functional properties of CCN proteins
.
Vitam Horm
.
2005
;
70
:
69
103
.
[PubMed]
0083-6729
30.
Arnott
JA
,
Lambi
AG
,
Mundy
C
,
Hendesi
H
,
Pixley
RA
,
Owen
TA
, et al
The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis
.
Crit Rev Eukaryot Gene Expr
.
2011
;
21
(
1
):
43
69
.
[PubMed]
1045-4403
31.
Boor
P
,
Floege
J
.
Chronic kidney disease growth factors in renal fibrosis
.
Clin Exp Pharmacol Physiol
.
2011
Jul
;
38
(
7
):
441
50
.
[PubMed]
0305-1870
32.
Dhar
A
,
Ray
A
.
The CCN family proteins in carcinogenesis
.
Exp Oncol
.
2010
Mar
;
32
(
1
):
2
9
.
[PubMed]
1812-9269
33.
Jüngel
A
,
Distler
JH
,
Gay
S
,
Distler
O
.
Epigenetic modifications: novel therapeutic strategies for systemic sclerosis?
Expert Rev Clin Immunol
.
2011
Jul
;
7
(
4
):
475
80
.
[PubMed]
1744-666X
34.
Li
GM
,
Fan
JG
.
[The role of CTGF in mediating hepatocytes epithelial-to-mesenchymal transition and hepatic fibrogenesis]
.
Zhonghua Gan Zang Bing Za Zhi
.
2011
Oct
;
19
(
10
):
795
7
.
[PubMed]
1007-3418
35.
Phanish
MK
,
Winn
SK
,
Dockrell
ME
.
Connective tissue growth factor-(CTGF, CCN2)—a marker, mediator and therapeutic target for renal fibrosis
.
Nephron, Exp Nephrol
.
2010
;
114
(
3
):
e83
92
.
[PubMed]
1660-2129
36.
Gerritsen
KG
,
Abrahams
AC
,
Peters
HP
,
Nguyen
TQ
,
Koeners
MP
,
den Hoedt
CH
, et al
Effect of GFR on plasma N-terminal connective tissue growth factor (CTGF) concentrations
.
Am J Kidney Dis
.
2012
May
;
59
(
5
):
619
27
.
[PubMed]
0272-6386
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.